Serca Pharmaceuticals presents first-in-class strategy for game-changing, post heart-attack cardioprotection at the European Society of Cardiology Congress 2023
/PRNewswire/ -- Serca Pharmaceuticals, a cardioprotection company that is developing 13-M, a novel first-in-class treatment for minimising the tissue damage...
Source: prnewswire.com